NASDAQ · MTVA
Healthcare · Biotechnology
$1.46
Up+$0.02 (+1.39%)
Updated Aug 22, 2026, 9:28 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
MTVA closed at $1.46 after 21 trading sessions, down 1.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.45 | $1.495 | $1.45 | $1.46 | 42.61K |
| Aug 20, 2026 | $1.47 | $1.47 | $1.43 | $1.44 | 42.17K |
| Aug 19, 2026 | $1.46 | $1.50 | $1.4424 | $1.47 | 86.32K |
| Aug 18, 2026 | $1.48 | $1.53 | $1.4353 | $1.49 | 74.87K |
| Aug 17, 2026 | $1.50 | $1.535 | $1.46 | $1.48 | 59.06K |
| Aug 14, 2026 | $1.47 | $1.52 | $1.4636 | $1.49 | 69.21K |
| Aug 13, 2026 | $1.47 | $1.481 | $1.43 | $1.46 | 141.73K |
| Aug 12, 2026 | $1.45 | $1.52 | $1.42 | $1.47 | 211.79K |
| Aug 11, 2026 | $1.45 | $1.47 | $1.42 | $1.42 | 51.61K |
| Aug 10, 2026 | $1.44 | $1.50 | $1.43 | $1.43 | 76.77K |
| Aug 7, 2026 | $1.43 | $1.54 | $1.43 | $1.49 | 108.08K |
| Aug 6, 2026 | $1.4894 | $1.505 | $1.45 | $1.45 | 37.44K |
| Aug 5, 2026 | $1.48 | $1.51 | $1.44 | $1.49 | 46.95K |
| Aug 4, 2026 | $1.48 | $1.53 | $1.46 | $1.46 | 64.23K |
| Aug 3, 2026 | $1.48 | $1.56 | $1.4507 | $1.48 | 35.36K |
| Jul 31, 2026 | $1.41 | $1.46 | $1.38 | $1.42 | 133.2K |
| Jul 30, 2026 | $1.47 | $1.47 | $1.41 | $1.44 | 56.98K |
| Jul 29, 2026 | $1.4231 | $1.49 | $1.41 | $1.44 | 54.81K |
| Jul 28, 2026 | $1.45 | $1.455 | $1.3901 | $1.43 | 55.02K |
| Jul 27, 2026 | $1.49 | $1.52 | $1.42 | $1.45 | 96.52K |
| Jul 24, 2026 | $1.47 | $1.5391 | $1.46 | $1.48 | 71.19K |
The latest Smart Investors Daily articles mentioning MTVA.
MTVA research
Company profile and research snapshot.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | HC Wainwright & Co. | Buy | — |
| May 19, 2025 | Maxim Group | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 12, 2026
By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 MetaVia, Inc. (NASDAQ: MTVA) is currently conducting Part 3 of the Phase 1 study of DA-1726, the company’s oxyntomodulin analog agonist that targets glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), for the treatment of obesity. The
Benzinga · Aug 6, 2026
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.82) by 9.76 percent. This is a 68.53 percent increase over losses of $(2.86) per share from the
Benzinga · Jul 10, 2026
HC Wainwright & Co. analyst Andrew S. Fein reiterates MetaVia (NASDAQ:MTVA) with a Buy and maintains $20 price target.
Benzinga · Jul 9, 2026
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mgTopline Data Remains on Track for Fourth Quarter 2026CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MTVA.
